BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23083832)

  • 1. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.
    Agell L; Hernández S; Nonell L; Lorenzo M; Puigdecanet E; de Muga S; Juanpere N; Bermudo R; Fernández PL; Lorente JA; Serrano S; Lloreta J
    Am J Pathol; 2012 Nov; 181(5):1585-94. PubMed ID: 23083832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues.
    Yousef GM; Stephan C; Scorilas A; Ellatif MA; Jung K; Kristiansen G; Jung M; Polymeris ME; Diamandis EP
    Prostate; 2003 Sep; 56(4):287-92. PubMed ID: 12858357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
    Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
    Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GREB1 tissue expression is associated with organ-confined prostate cancer.
    Antunes AA; Leite KR; Reis ST; Sousa-Canavez JM; Camara-Lopes LH; Dall'oglio MF; Srougi M
    Urol Oncol; 2012; 30(1):16-20. PubMed ID: 19945309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
    Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
    Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature.
    Lapointe J; Malhotra S; Higgins JP; Bair E; Thompson M; Salari K; Giacomini CP; Ferrari M; Montgomery K; Tibshirani R; van de Rijn M; Brooks JD; Pollack JR
    Am J Surg Pathol; 2008 Feb; 32(2):205-9. PubMed ID: 18223322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
    Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
    Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression.
    Hayashi T; Sentani K; Oue N; Ohara S; Teishima J; Anami K; Sakamoto N; Matsubara A; Yasui W
    Pathobiology; 2013; 80(2):60-9. PubMed ID: 22948749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.
    Tsunoda T; Furusato B; Takashima Y; Ravulapalli S; Dobi A; Srivastava S; McLeod DG; Sesterhenn IA; Ornstein DK; Shirasawa S
    Prostate; 2009 Sep; 69(13):1398-403. PubMed ID: 19479898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
    Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
    Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying molecular features for prostate cancer with Gleason 7 based on microarray gene expression profiles.
    Bălăcescu L; Bălăcescu O; Crişan N; Fetica B; Petruţ B; Bungărdean C; Rus M; Tudoran O; Meurice G; Irimie A; Dragoş N; Berindan-Neagoe I
    Rom J Morphol Embryol; 2011; 52(4):1195-202. PubMed ID: 22203922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
    Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
    Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
    Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
    Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of PHLDA1 gene expression is associated with breast cancer progression.
    Nagai MA; Fregnani JH; Netto MM; Brentani MM; Soares FA
    Breast Cancer Res Treat; 2007 Nov; 106(1):49-56. PubMed ID: 17211533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis.
    Cottrell S; Jung K; Kristiansen G; Eltze E; Semjonow A; Ittmann M; Hartmann A; Stamey T; Haefliger C; Weiss G
    J Urol; 2007 May; 177(5):1753-8. PubMed ID: 17437806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues.
    Yousef GM; Scorilas A; Chang A; Rendl L; Diamandis M; Jung K; Diamandis EP
    Prostate; 2002 May; 51(2):126-32. PubMed ID: 11948967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.